Day 1 ASCO24 Highlights by Oncology Brothers
Oncology Brothers shared on X:
Day 1 ASCO24 Highlights:
1. CROWN: Lorlatinib in ALK mNSCLC
2. PALOMA3: SC Amivantamab in EGFR mNSCLS
3. MARIPOSA: Ami in EGFR mNSCLC
4. GlobalOncCoP (Inas Abuali)
5. Social Media: Leveraging this (Fumiko Ladd Chino, Eric K. Singhi)
1. CROWN: Phase III, n= 296, Lorlatinib vs. Crizotinib ALK plus mNSCLC – mPFS not reached for lorlatinib and 9.1 months with crizotinib (HR:0.19).
5 year PFS 60% with lorlatinib and 8% with crizotinib.
Improved intracranial progression (HR: 0.06). AEs: with lorlatinib: HLD, weight gain.
2. PALOMA3: Phase 3, SC amivantamab plus Laz vs IV ami plus laz in mEGFR refractory mNSCLC
- Less IRRs (13% vs IV 66%)
- Improved VTE with SC
- Similar ORR .
3. MARIPOSA: Phase III, n= 1074, 1L Ami plus lazertinib in EGFR mNSCLC for high risk patients/biomarker update.
- High risk features are common upfront
- Improved PFS in ALL high risk features (HR: 0.49 to 0.71)
4. GlobalOncCoP: Barrier to access/amplification/representation by LMIC
- 40% ASCO members are outside the US
- Importance of global oncology research/representation/outreach
- Great to see Eric Small being there and fully supporting this initiative.
5. Social Media: Leveraging social media early in your career
- Use it to build your brand
- Use it to stay up to date
- Engage with patient and medical communities”
Source: Oncology Brothers/X